MPM BioVentures 2014, L.P.

13D and 13G Filings

13D/G filings: 13D on 4 securities
Location: Cambridge, MA
CIK: 0001609492
Form D filings: 3 filings
All SEC filings: View on sec.gov

Issuer	Symbol	CUSIP	% of Class	Shares	Form	Filed
Schedule 13D · 4 securities · may seek to influence control
Entrada Therapeutics, Inc. 13D/A TRDA · 29384C108	TRDA	29384C108	9.9%	3,885,115	13D/A	9/10/2026 Event 9/8/2026
MPM BioVentures 2014, L.P.			4.5%	1,764,167
MPM BioVentures 2014 (B), L.P.			0.3%	117,667
MPM Asset Management Investors BV2014 LLC			0.2%	60,722
MPM BioVentures 2014 GP LLC			4.8%	1,881,834
MPM BioVentures 2014 LLC			5.0%	1,942,556
MPM Bioventures 2018, L.P.			4.7%	1,810,592
MPM Bioventures 2018 (B), L.P.			0.2%	96,232
MPM Asset Management Investors BV2018 LLC			0.1%	35,735
MPM BioVentures 2018 GP LLC			4.9%	1,906,824
MPM BioVentures 2018 LLC			5.0%	1,942,559
Ansbert Gadicke			9.9%	3,885,115
Luke Evnin			9.9%	3,885,115
Todd Foley			9.9%	3,885,115
Werewolf Therapeutics, Inc. 13D/A HOWL · 95075A107	HOWL	95075A107	3.8%	1,826,646	13D/A	5/12/2026 Event 5/8/2026
MPM BioVentures 2014, L.P.			1.6%	792,254
MPM BioVentures 2014 (B), L.P.			0.1%	52,840
MPM Asset Management Investors BV2014 LLC			0.1%	27,267
UBS Oncology Impact Fund L.P.			1.3%	655,471
MPM BioVentures 2014 GP LLC			1.7%	845,094
MPM BioVentures 2014 LLC			1.8%	872,361
Oncology Impact Fund (Cayman) Management L.P.			1.3%	655,471
MPM BioImpact LLC			1.3%	655,471
Ansbert Gadicke			3.8%	1,826,646
Luke Evnin			2.4%	1,171,175
Todd Foley			1.8%	872,361
MPM Asset Management LLC			0.3%	125,480
MPM Oncology Innovations Fund LP			0.4%	173,334
MPM Oncology Innovations Fund GP LLC			0.4%	173,334
iTeos Therapeutics, Inc. 13D/A ITOS · 46565G104	ITOS	46565G104	4.7%	1,803,996	13D/A	5/15/2025 Event 5/13/2025
MPM BioVentures 2014, L.P.			1.6%	621,312
MPM BioVentures 2014 (B), L.P.			0.1%	39,135
MPM Asset Management Investors BV2014 LLC			0.1%	21,385
MPM Bioventures 2018, L.P.			1.0%	392,407
MPM Bioventures 2018 (B), L.P.			0.1%	19,697
MPM Asset Management Investors BV2018 LLC			0%	7,749
UBS Oncology Impact Fund L.P.			1.8%	702,311
MPM BioVentures 2014 GP LLC			1.7%	660,447
MPM BioVentures 2014 LLC			1.8%	681,832
MPM BioVentures 2018 GP LLC			1.1%	412,104
MPM BioVentures 2018 LLC			1.1%	419,853
Oncology Impact Fund (Cayman) Management L.P.			1.8%	702,311
MPM BioImpact LLC			1.8%	702,311
Ansbert Gadicke			4.7%	1,803,996
Luke Evnin			2.9%	1,101,685
Todd Foley			2.9%	1,101,685
Repare Therapeutics Inc. 13D/A RPTX · 760273102	RPTX	760273102	4.6%	1,941,242	13D/A	1/31/2025 Event 1/31/2025
MPM BioVentures 2014, L.P.			2.4%	1,018,345
MPM BioVentures 2014 (B), L.P.			0.2%	67,921
MPM Asset Management Investors BV2014 LLC			0.1%	35,052
UBS Oncology Impact Fund L.P.			1.9%	819,924
MPM BioVentures 2014 GP LLC			2.6%	1,086,266
MPM BioVentures 2014 LLC			2.6%	1,121,318
Oncology Impact Fund (Cayman) Management L.P.			1.9%	819,924
MPM BioImpact LLC			1.9%	819,924
Ansbert Gadicke			4.6%	1,941,242
Luke Evnin			2.6%	1,121,318
Todd Foley			2.6%	1,121,318

Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.